BMO Capital Markets Reaffirms Outperform Rating for Silence Therapeutics (NASDAQ:SLN)

Silence Therapeutics (NASDAQ:SLN)‘s stock had its “outperform” rating restated by equities research analysts at BMO Capital Markets in a note issued to investors on Monday,Briefing.com Automated Import reports.

SLN has been the subject of several other reports. HC Wainwright reiterated a “buy” rating and set a $75.00 target price on shares of Silence Therapeutics in a research note on Friday, November 15th. William Blair reaffirmed an “outperform” rating on shares of Silence Therapeutics in a report on Tuesday, November 19th. Jefferies Financial Group started coverage on shares of Silence Therapeutics in a report on Tuesday, September 3rd. They set a “buy” rating and a $40.00 price objective on the stock. Morgan Stanley reiterated an “overweight” rating and set a $49.00 price target on shares of Silence Therapeutics in a report on Tuesday, October 8th. Finally, Chardan Capital reissued a “buy” rating and set a $55.00 price objective on shares of Silence Therapeutics in a report on Thursday, November 14th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $57.20.

Silence Therapeutics Trading Up 5.1 %

SLN stock traded up $0.40 during midday trading on Monday, hitting $8.32. The stock had a trading volume of 111,708 shares, compared to its average volume of 248,636. Silence Therapeutics has a 52 week low of $5.81 and a 52 week high of $27.72. The firm has a market capitalization of $249.00 million, a price-to-earnings ratio of -5.10 and a beta of 1.30. The stock has a 50-day simple moving average of $15.83 and a 200 day simple moving average of $18.16.

Hedge Funds Weigh In On Silence Therapeutics

Institutional investors have recently bought and sold shares of the company. Eventide Asset Management LLC acquired a new stake in shares of Silence Therapeutics in the third quarter worth approximately $11,635,000. First Turn Management LLC acquired a new stake in shares of Silence Therapeutics in the second quarter valued at approximately $10,209,000. Millennium Management LLC increased its position in shares of Silence Therapeutics by 91.2% during the 2nd quarter. Millennium Management LLC now owns 782,941 shares of the company’s stock valued at $14,876,000 after purchasing an additional 373,523 shares during the period. SG Americas Securities LLC lifted its position in shares of Silence Therapeutics by 4,802.8% during the 2nd quarter. SG Americas Securities LLC now owns 343,196 shares of the company’s stock valued at $6,521,000 after acquiring an additional 336,196 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its holdings in shares of Silence Therapeutics by 219.3% in the third quarter. Point72 Asset Management L.P. now owns 467,800 shares of the company’s stock worth $8,505,000 after buying an additional 321,300 shares during the period. 98.73% of the stock is owned by institutional investors and hedge funds.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.